Spironolactone and Doxazosin Treatment in Patients With Resistant Hypertension;Uso de espironolactona o doxazosina en pacientes con hipertensión arterial refractaria

Revista Espanola de Cardiologia

Volumn 62, Issue 2, 2009, Pages 158-166

  Rodilla, Enrique ^a,b   Costa, José A ^b   Pérez Lahiguera, Francisco ^a,b   Baldó, Emilio ^b   González, Carmen ^b   Pascual, José M ^a,b,c  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL DE SAGUNTO   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Doxazosin; Refractory hypertension; Resistant hypertension; Spironolactone

Indexed keywords

DOXAZOSIN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DOXAZOSIN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 60749131097     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)70158-7     Document Type: Article

References (31)

1. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
2. Guidelines Committee. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87.
3. Kaplan N.M. Resistant hypertension. J Hypertens 23 (2005) 1441-1444
4. Park J., and Campese V. Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich) 9 Suppl 1 (2007) 7-12
5. Papadopoulos D.P., and Papademetriou V. Resistant hypertension: diagnosis and management. J Cardiovasc Pharmacol Ther 11 (2006) 113-118
6. Moser M., and Setaro J.F. Clinical practice. Resistant or difficultto- control hipertensión. N Engl J Med 355 (2006) 385-392
7. Taler S.J. Treatment of resistant hypertension. Curr Hypertens Rep 7 (2005) 323-329
8. Ouzan J., Perault C., Lincoff A.M., Carré E., and Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15 (2002) 333-339
9. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
10. Calhoun D.A. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens 9 Suppl 1 (2007) 19-24
11. Rodilla E., Costa J.A., Pérez-Lahiguera F., González C., and Pascual J.M. Respuesta antihipertensiva a la espironolactona en pacientes con hipertensión arterial refractaria. Med Clin (Barc) 131 (2008) 406-411
12. Black H.R., Solins J.S., and Garofalo J.L. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: A randomized, placebo-controlled study. Am J Hypertens 13 (2000) 468-474
13. Black H.R., Keck M., Meredith P., Bullen K., Quinn S., and Kornen A. Controlled-Release Doxazosin as Combination Therapy in Hypertension: The GATES Study. J Clin Hypertens 8 (2006) 159-166
14. Pessina A.C., Ciccariello L., Perrone F., Stoico V., Gussoni G., Scotti A., et al. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 16 (2006) 137-147
15. Robles N.R., Gómez Campderá F., Ocón I., Manjón M., Pastors L., Herrera J., et al. Doxazosina asociada a la combinación bloqueante del eje-renina-angiotensina y calcioantagonista en pacientes con insuficiencia renal crónica. Nefrologia 25 (2005) 515-520
16. Petrie J.C., O'Brien E.T., Littler W.A., and De Swiet M. Recommendations on blood pressure measurement. Br Med J (Clin Res Ed) 293 (1986) 611-615
17. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
19. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26 Suppl 1:5-20.
20. Chapman N., Dobson J., Wilson S., Dahlöf B., Sever P.S., Wedel H., et al., On behalf of the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
21. Mediavilla García J.D., Sabio J.M., Fernández-Torres C., Aliaga Martínez L., and Jiménez-Alonso J. Efecto de la doxazosina de liberación modificada en la presión arterial, la resistencia a la insulina y la secreción de catecolaminas en pacientes con hipertensión arterial resistente verdadera. Med Clin (Barc) 123 (2004) 297-299
22. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 (2004) 139-185
23. Fardella C.E., Mosso L., Gómez-Sánchez C., Cortes P., Soto J., Gómez L., et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 (2000) 1863-1867
24. Plouin P.F., and Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits?. Eur J Endocrinol 151 (2004) 305-308
25. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117 (2008) 510-526
26. Marín R., De la Sierra A., Armario P., Campo C., Banegas J.R., and Gorostidi M. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA). Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc) 125 (2005) 24-34
27. Rodilla E., García L., Merino C., Costa J.A., González C., and Pascual J.M. Importancia del síndrome metabólico en el control de la presión arterial y de la dislipemia. Med Clin (Barc) 123 (2004) 601-605
28. Pascual J.M., Baldó E., Bertolín V., Rovira E., Gonzalvo F., González C., et al. Presión arterial ambulatoria e hipertrofia ventricular izquierda en hipertensos no tratados. Med Clin (Barc) 112 (1999) 166-170
29. Pascual J.M., Rodilla E., Miralles A., González C., and Redón J. Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study. J Hypertens 24 (2006) 2277-2284
30. Pascual J.M., Rodilla E., González C., Pérez-Hoyos S., and Redón J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 45 (2005) 1125-1130
31. Redón J., Campos C., Narciso M.L., Rodicio J.L., Pascual J.M., and Ruilope L.M. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 31 (1998) 712-718